{"gene":"VEGFC","run_date":"2026-04-28T23:00:23","timeline":{"discoveries":[{"year":1997,"finding":"Stepwise proteolytic processing of the VEGF-C precursor generates several forms with progressively increased activity toward VEGFR-3; only the fully processed (mature) form can activate VEGFR-2. Mature VEGF-C binds VEGFR-3 (Kd=135 pM) and VEGFR-2 (Kd=410 pM), increases vascular permeability, and promotes endothelial cell migration and proliferation. Unlike other PDGF/VEGF family members, mature VEGF-C forms predominantly non-covalent homodimers.","method":"Recombinant protein production in yeast, receptor-binding assays, receptor phosphorylation assays, endothelial cell proliferation/migration assays, vascular permeability assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding, mutagenesis-equivalent processing studies, multiple orthogonal functional assays; highly cited foundational paper","pmids":["9233800"],"is_preprint":false},{"year":2003,"finding":"The proprotein convertases furin, PC5, and PC7 cleave proVEGF-C at the dibasic motif HSIIRR↓SL to generate mature VEGF-C. Mutation of this cleavage site (HSIIRR→HSIISS) blocks processing and abolishes VEGF-C-induced angiogenesis, lymphangiogenesis, and tumor growth in vivo, demonstrating that proteolytic processing by PCs is required for VEGF-C bioactivity.","method":"Cotransfection in furin-deficient LoVo cells, in vitro fluorogenic peptide cleavage assay, site-directed mutagenesis of cleavage site, subcutaneous tumor implantation in nude mice","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay with mutagenesis and in vivo validation; multiple orthogonal methods","pmids":["12782675"],"is_preprint":false},{"year":2006,"finding":"VEGF-C and VEGF-D directly bind neuropilin-2 (NP2) in a heparin-independent manner (VEGF-C) or heparin-dependent manner (VEGF-D). Upon VEGF-C or VEGF-D stimulation, NP2 co-internalizes with VEGFR-3 into endocytic vesicles of lymphatic endothelial cells, and NP2 co-precipitates with VEGFR-3, indicating NP2 participates in an active signaling complex with VEGFR-3.","method":"In vitro binding studies, domain-mapping experiments, co-internalization imaging, co-immunoprecipitation","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding and co-IP with functional co-internalization evidence; multiple orthogonal approaches","pmids":["16816121"],"is_preprint":false},{"year":2004,"finding":"VEGF-C (and VEGF-D) are direct ligands for the integrin α9β1. Cells expressing α9β1 adhere to and migrate on VEGF-C in a concentration-dependent, antibody-blockable manner; recombinant VEGF-C binds purified α9β1 integrin in a dose- and cation-dependent solid-phase assay; in cells lacking cognate VEGF receptors, VEGF-C induces α9β1-dependent ERK and paxillin phosphorylation.","method":"Cell adhesion and migration assays with α9β1-transfected cells, function-blocking antibody, solid-phase binding with purified integrin, signaling assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding to purified protein, functional cell assays, signaling readouts; multiple orthogonal methods","pmids":["15590642"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of the VEGF-C C-terminus in complex with the ligand-binding domains (b1) of neuropilin-2 reveals that a cryptic Nrp2-binding motif is exposed only upon C-terminal proteolytic maturation of VEGF-C. The endogenous secreted splice form s9Nrp2 forms a stable dimer that potently inhibits VEGF-C/Nrp2 binding and downstream cellular signaling.","method":"X-ray crystallography, biochemical binding assays, cell-based signaling assays","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation; demonstrates structural mechanism of proteolysis-regulated Nrp2 binding","pmids":["25752543"],"is_preprint":false},{"year":2000,"finding":"VEGF-C signals through both VEGFR-2 and VEGFR-3 during vasculogenesis and hematopoiesis. In VEGFR-3-deficient embryos, excess VEGF-C signals through VEGFR-2 and disturbs vasculogenesis and hematopoiesis; trapping VEGF-C with VEGFR-3-Fc in these embryos rescues vascular bed formation and partially rescues hematopoiesis, indicating that VEGFR-3 binding regulates the available pool of VEGF-C for VEGFR-2 signaling.","method":"Para-aortic splanchnopleural mesoderm coculture with stromal cells, soluble receptor competitor proteins, VEGFR-3 knockout embryos, rescue experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with knockout embryos and receptor-trap rescue; multiple orthogonal genetic and pharmacological tools","pmids":["11090062"],"is_preprint":false},{"year":2008,"finding":"RANKL stimulates osteoclasts and their precursors to express and secrete VEGF-C through an NF-κB-dependent mechanism (reduced in NF-κBp50/p52 double-knockout cells or with NF-κB inhibitor). VEGF-C then acts as an autocrine factor via VEGFR-3 on osteoclasts: it stimulates Src phosphorylation and enhances bone resorption, an effect blocked by VEGFR3:Fc or in Src-knockout osteoclasts.","method":"Real-time RT-PCR, Western blot, immunostaining, osteoclastogenesis and pit resorption assays, NF-κB inhibition, knockout osteoclasts, receptor-blocking fusion protein","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic loss-of-function models, receptor-specific blocking, functional readout; strong mechanistic evidence","pmids":["18359770"],"is_preprint":false},{"year":2015,"finding":"VEGF-C is required for maintenance of intestinal lymphatic vessels (lacteals) in adult mice; conditional Vegfc deletion leads to lacteal atrophy, defective dietary lipid absorption, and increased fecal excretion of cholesterol and fatty acids. VEGF-C is expressed by a subset of smooth muscle cells adjacent to the lacteals. Deletion also causes resistance to high-fat diet-induced obesity.","method":"Conditional Vegfc gene deletion in adult mice, histology, lipid absorption assays, fecal fat measurement, high-fat diet challenge","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — clean conditional knockout with specific functional phenotype (lipid absorption) and defined cellular source","pmids":["26459520"],"is_preprint":false},{"year":2016,"finding":"VEGF-C plays a critical role in the transition from primitive to definitive (fetal liver) erythropoiesis. Vegfc deletion at E7.5 causes defective fetal erythropoiesis: anemia, lack of enucleated red blood cells, and reduced macrophage and erythroid cell numbers in fetal liver due to decreased proliferation and increased apoptosis. VEGF-C loss reduces α4-integrin expression on erythro-myeloid progenitors, impairing their colonization of the fetal liver.","method":"Conditional Vegfc gene deletion in mouse embryos, flow cytometry, colony assays, α4-integrin expression analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — conditional knockout with mechanistic cellular readout (integrin-dependent progenitor migration) and multiple hematopoietic phenotypes","pmids":["27343251"],"is_preprint":false},{"year":2019,"finding":"VEGF-C (and VEGF-D) are cleaved and activated by thrombin and plasmin, serine proteases generated during hemostasis and wound healing. Platelets accelerate lymphatic growth after injury in vivo in a VEGF-C-dependent manner (but not VEGF-D-dependent), establishing a molecular link between hemostasis/platelet activation and lymphangiogenesis.","method":"In vitro cleavage assays with thrombin and plasmin, tail-wounding assay in mice, genetic studies with platelet-specific deletion, lymphangiogenesis quantification","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro biochemical cleavage assays combined with in vivo genetic studies; multiple orthogonal approaches","pmids":["31562136"],"is_preprint":false},{"year":2011,"finding":"VEGF-C binds to heparan sulfate on lymphatic endothelial cells; heparin interference or heparinase treatment reduces VEGF-C-induced ERK1/2 and VEGFR-3 phosphorylation. Silencing of lymphatic Ndst1 (a heparan sulfate biosynthetic enzyme) inhibits VEGF-C-mediated ERK1/2 activation, abrogates cell-surface VEGFR-3-dependent VEGF-C binding, and reduces cell growth, migration, and collagen matrix sprouting in response to VEGF-C.","method":"Heparan sulfate binding assays, heparinase treatment, siRNA knockdown of Ndst1, phosphorylation assays, scratch migration assays, ex vivo sprouting in collagen matrix","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple loss-of-function approaches (pharmacological and genetic) with signaling and functional readouts","pmids":["21343305"],"is_preprint":false},{"year":2012,"finding":"FGF-2 and VEGF-C collaboratively promote lymphangiogenesis; VEGFR-3-mediated signaling is required for lymphatic tip cell formation in both FGF-2- and VEGF-C-induced lymphangiogenesis. A VEGFR-3-specific neutralizing antibody markedly inhibits FGF-2-induced lymphangiogenesis, placing VEGFR-3 downstream of FGF-2/FGFR-1 for tip cell formation.","method":"Mouse cornea lymphangiogenesis assay, VEGFR-3-neutralizing antibody, in vivo coimplantation, tumor metastasis models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo epistasis with neutralizing antibody; single lab","pmids":["22967508"],"is_preprint":false},{"year":2006,"finding":"COX-2 promotes VEGF-C synthesis in breast cancer cells via prostaglandin E2 (PGE2) signaling through EP1 and EP4 receptors; EP1 and EP4 antagonists inhibit VEGF-C production. VEGF-C secretion also requires Her-2/neu, Src, and p38 MAPK kinase activities, as inhibitors of these kinases block VEGF-C secretion.","method":"COX-2 siRNA knockdown, COX inhibitors, EP receptor antagonists, kinase inhibitors, ELISA for VEGF-C secretion, LYVE-1 immunostaining in breast cancer tissues","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological pathway dissection with multiple inhibitors; single lab with moderate mechanistic depth","pmids":["16570043"],"is_preprint":false},{"year":2012,"finding":"The transcription factor SIX1 directly induces transcription of VEGF-C; SIX1-induced VEGF-C is required for peritumoral and intratumoral lymphangiogenesis and lymphatic metastasis of breast cancer cells in immunocompromised mice.","method":"SIX1 overexpression and knockdown in human breast cancer cells, mouse xenograft models, lymphangiogenesis quantification, VEGF-C rescue experiments","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 — gain/loss of function with VEGF-C rescue experiment; single lab","pmids":["22466647"],"is_preprint":false},{"year":2014,"finding":"Hypoxia reduces VEGF-C transcription and cap-dependent translation via upregulation of hypophosphorylated 4E-BP1, but induces VEGF-C translation through an internal ribosome entry site (IRES)-dependent, HIF-1α-independent mechanism. IRES-dependent VEGF-C translation is higher in metastasizing tumor cells within lymph nodes (severely hypoxic) than in primary tumors.","method":"IRES reporter assays, 4E-BP1 phosphorylation analysis, HIF-1α knockdown, cap-dependent vs. IRES-dependent translation assays, in vivo tumor/lymph node comparison","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 — IRES reporter assays combined with genetic knockdown and in vivo validation; multiple orthogonal methods","pmids":["24388748"],"is_preprint":false},{"year":2009,"finding":"Androgens regulate VEGF-C expression: androgen deprivation in LNCaP prostate cancer cells activates the small GTPase RalA (via elevated reactive oxygen species), and RalA activation leads to VEGF-C upregulation. The FOXO-1 transcription factor (activated by SIRT-1 downstream of reduced IGF-IR signaling) also mediates VEGF-C transcriptional upregulation upon androgen withdrawal.","method":"RalA activation assays, ROS measurement, RalA dominant-negative/knockdown, FOXO-1 siRNA, VEGF-C mRNA/protein measurement","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic and pharmacological pathway dissection in cell lines; single lab","pmids":["16964283"],"is_preprint":false},{"year":2021,"finding":"Nicotine downregulates the deubiquitinase OTUD3, which normally stabilizes the mRNA-binding protein ZFP36 by inhibiting FBXW7-mediated K48-linked polyubiquitination. ZFP36 binds the VEGF-C 3'-UTR and recruits an RNA-degrading complex to induce VEGF-C mRNA decay; loss of OTUD3/ZFP36 leads to VEGF-C mRNA stabilization and increased VEGF-C production, promoting lymphatic metastasis.","method":"Co-immunoprecipitation, ubiquitination assays, RNA immunoprecipitation, RNA pulldown, mRNA stability assays, in vivo metastasis models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic chain established by RIP, RNA pulldown, ubiquitination assays, and in vivo validation; multiple orthogonal methods","pmids":["34853315"],"is_preprint":false},{"year":2020,"finding":"VEGF-C is transported by extracellular vesicles (EVs) from endometriotic cells to lymphatic endothelial cells where it enhances lymphangiogenic capacity. The orphan nuclear receptor COUP-TFII negatively regulates VEGF-C expression; proinflammatory cytokines suppress COUP-TFII, thereby inducing VEGF-C overexpression.","method":"Extracellular vesicle isolation and functional assays, COUP-TFII knockdown, cytokine treatment, autotransplanted mouse model of endometriosis, lenvatinib treatment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2-3 — EV-mediated transfer demonstrated functionally; COUP-TFII regulation shown by knockdown; single lab","pmids":["33004630"],"is_preprint":false},{"year":2020,"finding":"PIK3CA(H1047R)-driven lymphatic malformations grow in a VEGF-C-dependent manner; combined inhibition of VEGF-C (blocking VEGF-C/VEGFR3 signaling) and mTOR (downstream of PI3K) with rapamycin promotes regression of microcystic lymphatic malformations, whereas neither treatment alone is sufficient.","method":"Mouse model of PIK3CA(H1047R)-driven lymphatic malformations, VEGF-C inhibition, rapamycin treatment, epistasis by combined pharmacological blockade","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — genetic mouse model with pharmacological epistasis; single lab but rigorous in vivo design","pmids":["32513927"],"is_preprint":false},{"year":2020,"finding":"In intestinal villi, YAP/TAZ activity in PDGFRβ+ interstitial stromal cells drives VEGF-C secretion to maintain lacteal integrity and dietary fat uptake. Mechanical or osmotic stress regulates YAP/TAZ-dependent VEGF-C secretion in these cells; single-cell RNA sequencing identified distinct fibroblast subtypes near lacteals that upregulate Vegfc upon YAP/TAZ activation.","method":"Conditional YAP/TAZ hyperactivation or depletion in PDGFRβ+ cells, single-cell RNA sequencing, VEGF-C ELISA, lacteal morphology and fat uptake assays, mechanical/osmotic stress experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — clean conditional genetic models with scRNA-seq and functional phenotype; multiple orthogonal methods","pmids":["32796823"],"is_preprint":false},{"year":2009,"finding":"VEGF-C regulates capillary stabilization through paracrine induction of PDGF-B expression. In ischemic hindlimb, VEGFR-3 blockade not only diminishes lymphangiogenesis but also causes capillary dilation with mural cell dissociation; VEGF-C and PDGF-B expression are mutually dependent (blocking either reduces expression of the other), placing VEGF-C upstream of PDGF-B-mediated vessel stabilization.","method":"VEGFR-3 neutralizing antibody in ischemic hindlimb model, FGF-2 adenoviral gene transfer, real-time RT-PCR, histology, limb salvage/blood flow assessment","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 — in vivo pharmacological epistasis; single lab; indirect evidence for PDGF-B regulation","pmids":["19734356"],"is_preprint":false},{"year":2006,"finding":"VEGF-C promotes podocyte survival through an autocrine mechanism: ablation of VEGF-C or treatment with a VEGFR-2/-3 tyrosine kinase inhibitor reduces podocyte survival, and VEGF-C activates antiapoptotic PI3K/AKT and suppresses p38MAPK via VEGFR-2 (SU-5416 at VEGFR-1-specific concentration blocks VEGF-C survival effect, suggesting a VEGFR-1-containing complex may be involved).","method":"VEGF-C siRNA knockdown in human conditionally immortalized podocytes, cytotoxicity assays, kinase inhibitors (MAZ51, SU-5416), phosphorylation assays, intracellular calcium measurements, immunoprecipitation","journal":"American journal of physiology. Renal physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple pharmacological tools and siRNA in primary-like cells; single lab; receptor identity not fully resolved","pmids":["16525158"],"is_preprint":false},{"year":2018,"finding":"VEGF-C activates autocrine VEGFR-2 signaling in glioblastoma cells to promote cell survival and tumor growth; VEGF-C/VEGFR-2 interaction was detected by proximity ligation assay in surgical specimens. Targeting VEGF-C (but not bevacizumab, which targets VEGF-A) impairs glioblastoma tumor growth in vivo.","method":"RNA interference, proximity ligation assay, immunohistochemistry, patient-derived xenograft lines in vitro and in vivo","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 — RNAi with in vivo validation and proximity ligation assay for endogenous interaction; single lab","pmids":["29939339"],"is_preprint":false},{"year":2020,"finding":"VEGF-C secreted by EMT breast cancer cells activates non-canonical GLI signaling in neighboring epithelial breast cancer cells via NRP2 (a VEGF-C receptor), promoting their proliferation, migration, invasion, and metastasis. This paracrine VEGF-C/NRP2/GLI axis can be disrupted by VEGF-C inhibition in EMT cells or NRP2 knockdown in epithelial cells.","method":"VEGF-C knockdown, NRP2 knockdown, GLI signaling assays, in vivo metastasis models, conditioned medium experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 — genetic loss-of-function with in vivo validation; single lab; NRP2 as VEGF-C receptor in this context","pmids":["33299122"],"is_preprint":false},{"year":2020,"finding":"S1PR1 in lymphatic endothelial cells antagonizes laminar shear stress-induced VEGF-C/VEGFR3 signaling to promote lymphatic vascular quiescence. S1pr1 loss in LECs induces lymphatic hypersprouting and hyperbranching that can be rescued by reducing Vegfr3 gene dosage in vivo, placing S1PR1 as a negative regulator upstream of VEGF-C/VEGFR3-driven sprouting.","method":"Conditional S1pr1 knockout in LECs, Vegfr3 genetic rescue, laminar shear stress assays, signaling assays, in vivo vascular phenotyping","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis (double mutant rescue) with in vivo vascular phenotype; clean mechanistic pathway placement","pmids":["32544090"],"is_preprint":false},{"year":2009,"finding":"Gonadotropins (LH, FSH) induce VEGF-C expression in ovarian cancer cells via LEDGF/p75, which binds a stress-response element in the VEGF-C promoter (confirmed by chromatin immunoprecipitation); FSH augments LEDGF/p75 binding to the VEGF-C promoter. LEDGF siRNA, GnRH antagonist, or mutation of the stress-response element suppresses gonadotropin-induced VEGF-C expression.","method":"Chromatin immunoprecipitation, LEDGF siRNA, GnRH antagonist (cetrorelix), promoter mutation, ovariectomy mouse model, VEGF-C mRNA and promoter activity assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirms direct promoter binding; multiple genetic and pharmacological approaches; single lab","pmids":["19934313"],"is_preprint":false},{"year":2021,"finding":"VEGF-C, induced in mesenchymal stromal cells by steroids and TNFα, promotes CD8+ T cell proliferation via VEGFR-3 expressed on CD8+ T cells; VEGF-C augments PI3K/AKT signaling and downstream Cyclin D1 expression in CD8+ T cells. Blockade or genetic ablation of VEGFR3 in CD8+ T cells abolishes the VEGF-C-mediated immune-promoting effect.","method":"MSC-CD8+ T cell co-culture, VEGFR3 blockade antibody, conditional VEGFR3 knockout in T cells, PI3K/AKT signaling assays, in vivo GvHD model","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — genetic loss-of-function of receptor in CD8+ T cells combined with signaling assays; single lab","pmids":["34194927"],"is_preprint":false},{"year":2019,"finding":"Hes1, a transcription factor, directly binds and positively activates VEGF-C gene expression (genome-wide Hes1 occupancy analysis); elevated VEGF-C produced downstream of Hes1 attenuates TLR upstream signaling by inhibiting the adaptor WDFY1, thereby suppressing type I IFN production.","method":"Genome-wide ChIP-seq for Hes1 occupancy, Hes1 knockout mice, VEGF-C expression analysis, WDFY1 signaling assays, viral infection and lupus nephritis models","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-seq for direct binding combined with genetic knockout and functional immune phenotype; single lab","pmids":["31015298"],"is_preprint":false},{"year":2014,"finding":"SIX1 cooperates with TGFβ/SMAD2/3 signaling to enhance VEGF-C expression in cervical cancer cells; SIX1 augments TGFβ-induced SMAD2/3 activation, and together they produce much higher VEGF-C than either alone. Increased VEGF-C from SIX1-expressing tumor cells promotes lymphatic endothelial cell migration and tube formation and counteracts TGFβ's direct inhibitory effects on LECs.","method":"SIX1 overexpression/knockdown, TGFβ treatment, SMAD2/3 phosphorylation assays, VEGF-C promoter/expression assays, LEC migration and tube formation assays, in vivo lymphangiogenesis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple cell-based epistasis experiments; single lab","pmids":["25142796"],"is_preprint":false},{"year":2024,"finding":"Intracerebrospinal AAV-mediated VEGF-C overexpression enhances CSF drainage to deep cervical lymph nodes by promoting meningeal lymphatic vessel growth, upregulates neuroprotective signaling pathways, and reduces ischemic stroke injury in mice. Neuroprotective effects are lost upon cauterization of afferent lymphatics to the deep cervical lymph nodes, demonstrating that the effect is mediated through enhanced lymphatic drainage.","method":"AAV-mVEGF-C intracerebrospinal delivery, lymphatic cauterization, single-nucleus RNA sequencing, CSF drainage assays, ischemic stroke model (MRI, behavioral tests)","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic link established by lymphatic cauterization rescue experiment; multiple readouts; single lab","pmids":["38442272"],"is_preprint":false}],"current_model":"VEGF-C is secreted as a precursor that undergoes stepwise proteolytic processing by proprotein convertases (furin, PC5, PC7) and serine proteases (thrombin, plasmin) to generate mature forms with progressively higher affinity for VEGFR-3 and, for the fully processed form, VEGFR-2; mature VEGF-C also binds co-receptors neuropilin-2 (via a cryptic, proteolysis-exposed motif engaging the Nrp2-b1 domain, as revealed by crystal structure) and integrin α9β1, and heparan sulfate facilitates VEGFR-3 engagement; through VEGFR-3 and VEGFR-2 signaling, VEGF-C drives lymphangiogenesis, blood vascular angiogenesis, lymphatic vessel maintenance (particularly intestinal lacteals), fetal erythropoiesis, podocyte survival, osteoclast bone resorption, and CD8+ T cell proliferation, while its expression is regulated transcriptionally by NF-κB, SIX1, LEDGF/p75, FOXO-1, COX-2/PGE2, Hes1, YAP/TAZ, and post-transcriptionally by IRES-dependent translation under hypoxia and by the OTUD3/ZFP36 mRNA-decay axis."},"narrative":{"teleology":[{"year":1997,"claim":"Establishing that VEGF-C bioactivity requires stepwise proteolytic maturation resolved how a single precursor generates forms with differential receptor selectivity — only the fully processed mature form activates VEGFR-2, while intermediates activate VEGFR-3 alone.","evidence":"Recombinant VEGF-C processing in yeast, receptor-binding/phosphorylation assays, endothelial proliferation/migration/permeability assays","pmids":["9233800"],"confidence":"High","gaps":["Identity of the endogenous processing proteases was unknown","Structural basis for receptor selectivity of different processed forms unresolved","In vivo significance of differential receptor activation not tested"]},{"year":2003,"claim":"Identification of furin, PC5, and PC7 as the proprotein convertases that cleave proVEGF-C at the HSIIRR motif — and demonstration that mutating this site abolishes in vivo angiogenesis and lymphangiogenesis — established that PC-mediated processing is the gateway to VEGF-C bioactivity.","evidence":"Enzymatic cleavage assays in furin-deficient cells, site-directed mutagenesis, tumor implantation in nude mice","pmids":["12782675"],"confidence":"High","gaps":["Whether additional proteases contribute to VEGF-C activation in vivo remained open","Tissue-specific regulation of PC access to proVEGF-C unknown"]},{"year":2000,"claim":"Demonstrating that VEGF-C signals through both VEGFR-3 and VEGFR-2 during embryonic vasculogenesis and hematopoiesis, with VEGFR-3 acting as a sink to regulate VEGF-C availability for VEGFR-2, established the dual-receptor signaling logic governing VEGF-C function in development.","evidence":"VEGFR-3-deficient embryo cultures, soluble VEGFR-3-Fc rescue, hematopoietic colony assays","pmids":["11090062"],"confidence":"High","gaps":["Downstream intracellular pathways distinguishing VEGFR-2 vs VEGFR-3 signaling in hematopoiesis unresolved","Relative contribution of each receptor in different tissues unknown"]},{"year":2004,"claim":"Discovery of integrin α9β1 as a direct VEGF-C receptor that signals independently of VEGFR-2/VEGFR-3 expanded the receptor repertoire beyond tyrosine kinases and explained VEGF-C effects in VEGFR-negative cells.","evidence":"Solid-phase binding with purified integrin, adhesion/migration assays with α9β1-transfected cells, ERK/paxillin signaling in VEGFR-lacking cells","pmids":["15590642"],"confidence":"High","gaps":["Physiological context where α9β1 is the dominant VEGF-C receptor not defined","Structural basis for VEGF-C/α9β1 interaction unknown"]},{"year":2006,"claim":"Identification of neuropilin-2 as a VEGF-C co-receptor that co-internalizes with VEGFR-3 upon ligand stimulation established NRP2 as a component of the active lymphangiogenic signaling complex, and demonstration of VEGF-C's autocrine survival role in podocytes broadened its functions beyond vascular contexts.","evidence":"Binding assays, co-IP, co-internalization imaging for NRP2/VEGFR-3; siRNA, kinase inhibitors, and apoptosis assays in podocytes","pmids":["16816121","16525158"],"confidence":"High","gaps":["Structural mechanism of NRP2/VEGF-C interaction not yet resolved","Whether NRP2 modulates VEGFR-3 signaling quantitatively or qualitatively unknown"]},{"year":2008,"claim":"Showing that RANKL induces VEGF-C expression via NF-κB in osteoclasts, which then signals autocrinally through VEGFR-3/Src to enhance bone resorption, established the first non-vascular autocrine loop for VEGF-C and linked it to skeletal homeostasis.","evidence":"NF-κBp50/p52 double-knockout osteoclasts, VEGFR3:Fc blocking, Src-knockout osteoclasts, pit resorption assays","pmids":["18359770"],"confidence":"High","gaps":["Whether VEGF-C/VEGFR-3 signaling in osteoclasts is relevant in non-pathological bone remodeling unclear","Downstream effectors beyond Src not mapped"]},{"year":2009,"claim":"Dissection of transcriptional regulators — LEDGF/p75 binding the VEGF-C promoter downstream of gonadotropins, and FOXO-1 mediating androgen withdrawal-induced VEGF-C — revealed context-dependent transcriptional control linking hormonal cues to lymphangiogenic output.","evidence":"ChIP for LEDGF/p75 at VEGF-C promoter, siRNA, GnRH antagonist; RalA activation assays, FOXO-1 knockdown in prostate cancer cells","pmids":["19934313","16964283"],"confidence":"Medium","gaps":["Whether LEDGF/p75 and FOXO-1 cooperate or operate in distinct cellular contexts not tested","Full promoter architecture and enhancer landscape of VEGF-C uncharacterized"]},{"year":2011,"claim":"Demonstrating that heparan sulfate on lymphatic endothelial cells is required for VEGF-C binding to VEGFR-3 and for downstream ERK1/2 activation added a glycosaminoglycan co-receptor requirement to the VEGF-C signaling model.","evidence":"Heparinase treatment, Ndst1 siRNA knockdown, VEGFR-3 phosphorylation assays, sprouting assays in collagen matrices","pmids":["21343305"],"confidence":"High","gaps":["Specific heparan sulfate modifications (sulfation patterns) that mediate VEGF-C interaction unknown","Whether heparan sulfate requirement is shared across all VEGF-C target cell types not tested"]},{"year":2012,"claim":"SIX1 was identified as a direct transcriptional activator of VEGF-C that drives tumor lymphangiogenesis and lymphatic metastasis, providing a molecular link between a developmental transcription factor and tumor-associated lymphatic remodeling.","evidence":"SIX1 overexpression/knockdown in breast cancer cells, VEGF-C rescue, xenograft lymphangiogenesis quantification","pmids":["22466647"],"confidence":"Medium","gaps":["Whether SIX1 binds the VEGF-C promoter directly (ChIP) was not shown in this study","Relevance to non-neoplastic lymphangiogenesis not established"]},{"year":2014,"claim":"Discovery that hypoxia switches VEGF-C translation from cap-dependent to IRES-dependent (independent of HIF-1α) explained how VEGF-C protein production is sustained in severely hypoxic microenvironments such as tumor-draining lymph nodes.","evidence":"IRES reporter assays, 4E-BP1 phosphorylation analysis, HIF-1α knockdown, comparison of VEGF-C in primary tumors vs lymph node metastases","pmids":["24388748"],"confidence":"High","gaps":["IRES trans-acting factors that mediate VEGF-C IRES activity unidentified","Whether IRES-dependent translation is relevant in non-tumor hypoxia not tested"]},{"year":2015,"claim":"The crystal structure of the VEGF-C C-terminus bound to the NRP2-b1 domain revealed that proteolytic maturation exposes a cryptic NRP2-binding motif, providing the structural basis for how processing controls co-receptor engagement and offering a template for soluble NRP2-based inhibitors.","evidence":"X-ray crystallography, binding assays, cell-based signaling assays with soluble s9Nrp2 inhibitor","pmids":["25752543"],"confidence":"High","gaps":["Full ternary complex of VEGF-C/NRP2/VEGFR-3 not structurally resolved","Whether the s9Nrp2 decoy has therapeutic utility in vivo not established"]},{"year":2015,"claim":"Conditional Vegfc deletion in adult mice causing lacteal atrophy and defective lipid absorption proved that VEGF-C is continuously required for intestinal lymphatic maintenance, not only developmental lymphangiogenesis.","evidence":"Conditional Vegfc knockout in adult mice, histology, fecal fat measurements, high-fat diet challenge","pmids":["26459520"],"confidence":"High","gaps":["The specific VEGFR (VEGFR-2 vs VEGFR-3) mediating lacteal maintenance not genetically dissected","Whether VEGF-C from smooth muscle cells is the sole source or other cells contribute not excluded"]},{"year":2016,"claim":"Demonstrating that embryonic Vegfc deletion blocks the transition from primitive to definitive erythropoiesis — via reduced α4-integrin on progenitors impairing fetal liver colonization — revealed an unexpected hematopoietic role for VEGF-C beyond vascular development.","evidence":"Conditional Vegfc deletion at E7.5, flow cytometry, colony assays, α4-integrin expression analysis","pmids":["27343251"],"confidence":"High","gaps":["Whether VEGF-C regulates α4-integrin directly or indirectly unresolved","The receptor mediating this effect on erythro-myeloid progenitors not definitively identified"]},{"year":2019,"claim":"Identification of thrombin and plasmin as VEGF-C-activating proteases, and demonstration that platelets drive wound lymphangiogenesis via VEGF-C, established a molecular link between hemostasis and lymphatic repair.","evidence":"In vitro cleavage assays, platelet-specific genetic deletion, tail-wounding lymphangiogenesis quantification in mice","pmids":["31562136"],"confidence":"High","gaps":["Relative contributions of thrombin vs plasmin vs furin/PCs in wound healing not quantified","Whether platelet-derived VEGF-C is pre-stored or de novo synthesized not resolved"]},{"year":2019,"claim":"ChIP-seq identification of Hes1 as a direct transcriptional activator of VEGF-C, coupled with the finding that VEGF-C attenuates TLR signaling by suppressing WDFY1, revealed an immunomodulatory arm of VEGF-C function.","evidence":"Genome-wide Hes1 ChIP-seq, Hes1 knockout mice, WDFY1 signaling analysis, viral infection and lupus nephritis models","pmids":["31015298"],"confidence":"Medium","gaps":["Mechanism by which VEGF-C inhibits WDFY1 not fully elucidated","Whether this pathway operates in non-immune cell types unknown"]},{"year":2020,"claim":"Multiple 2020 studies converged on tissue-specific regulatory axes: YAP/TAZ in intestinal stromal cells drives VEGF-C for lacteal maintenance; S1PR1 in lymphatic endothelium antagonizes VEGF-C/VEGFR-3 to enforce vascular quiescence; and EV-mediated VEGF-C transport and COUP-TFII-dependent repression operate in endometriosis — collectively revealing that VEGF-C bioavailability is tuned by mechanosensitive, inflammatory, and vesicular mechanisms.","evidence":"Conditional YAP/TAZ models with scRNA-seq; conditional S1pr1 knockout with Vegfr3 genetic rescue; EV isolation and COUP-TFII knockdown in endometriosis models","pmids":["32796823","32544090","33004630"],"confidence":"High","gaps":["Whether YAP/TAZ regulation of VEGF-C extends to other organs not tested","Mechanotransduction pathway connecting shear stress to S1PR1-mediated VEGFR-3 suppression incompletely defined","COUP-TFII regulation confirmed in one disease context only"]},{"year":2021,"claim":"Discovery of the OTUD3/ZFP36 axis — where OTUD3 stabilizes ZFP36 to promote VEGF-C mRNA decay — established the first post-transcriptional regulatory circuit controlling VEGF-C abundance, and its disruption by nicotine explained increased lymphatic metastasis.","evidence":"Co-IP, ubiquitination assays, RNA immunoprecipitation, RNA pulldown, mRNA stability assays, in vivo metastasis models","pmids":["34853315"],"confidence":"High","gaps":["Whether other ARE-binding proteins besides ZFP36 target VEGF-C mRNA not examined","Generalizability beyond nicotine-exposed tumor context unknown"]},{"year":2021,"claim":"Demonstration that VEGF-C promotes CD8+ T cell proliferation via VEGFR-3/PI3K/AKT/Cyclin D1 expanded VEGF-C biology into adaptive immunity, showing it is not exclusively a vascular growth factor.","evidence":"MSC-CD8+ T cell co-culture, conditional VEGFR3 knockout in T cells, PI3K/AKT signaling, GvHD model","pmids":["34194927"],"confidence":"Medium","gaps":["Whether VEGF-C/VEGFR-3 signaling on T cells operates during normal immune responses not established","Interaction with other T cell co-stimulatory pathways not addressed"]},{"year":2024,"claim":"AAV-mediated VEGF-C overexpression in the CNS promoted meningeal lymphatic growth and enhanced CSF drainage, reducing ischemic stroke injury — an effect abolished by lymphatic cauterization — establishing VEGF-C-driven meningeal lymphangiogenesis as neuroprotective.","evidence":"AAV-mVEGF-C intracerebrospinal delivery, lymphatic cauterization, snRNA-seq, CSF drainage assays, stroke model with MRI and behavioral outcomes","pmids":["38442272"],"confidence":"Medium","gaps":["Whether endogenous meningeal VEGF-C plays a role in stroke outcome unknown","Neuroprotective pathways downstream of enhanced drainage not mechanistically defined","Translational relevance to human stroke not tested"]},{"year":null,"claim":"Major open questions include: the full ternary structure of VEGF-C/NRP2/VEGFR-3, how tissue-specific protease availability quantitatively tunes the VEGF-C activity gradient in vivo, the complete enhancer/promoter logic integrating the many identified transcription factors, and whether the immunomodulatory and hematopoietic functions of VEGF-C are clinically targetable independently of its lymphangiogenic role.","evidence":"","pmids":[],"confidence":"Low","gaps":["No ternary receptor complex structure available","Quantitative in vivo protease contribution mapping lacking","Integration of multiple transcriptional inputs at the VEGF-C locus not modeled"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,5,6,7,8,21,22,26]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,9,17]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,3,5,6,10,21,22,24,26]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5,8]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[26,27]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1,9]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[9]}],"complexes":[],"partners":["FLT4","KDR","NRP2","ITGA9","FURIN","ZFP36"],"other_free_text":[]},"mechanistic_narrative":"VEGF-C is a secreted lymphangiogenic and angiogenic growth factor that undergoes obligate stepwise proteolytic processing — by proprotein convertases (furin, PC5, PC7) and serine proteases (thrombin, plasmin) — to generate mature forms with progressively higher affinity for VEGFR-3 (Kd ~135 pM) and, for the fully processed form, VEGFR-2 (Kd ~410 pM); processing also exposes a cryptic neuropilin-2-binding motif whose structural basis has been defined by crystallography [PMID:9233800, PMID:12782675, PMID:31562136, PMID:25752543]. Mature VEGF-C additionally engages integrin α9β1 and heparan sulfate as co-receptors that facilitate VEGFR-3 signaling, and signals through PI3K/AKT and Src pathways to drive lymphangiogenesis, blood vascular angiogenesis, intestinal lacteal maintenance and dietary lipid absorption, fetal erythropoiesis, osteoclast-mediated bone resorption, podocyte survival, and CD8+ T cell proliferation [PMID:15590642, PMID:21343305, PMID:26459520, PMID:27343251, PMID:18359770, PMID:16525158, PMID:34194927]. VEGF-C transcription is driven by NF-κB, SIX1, LEDGF/p75, FOXO-1, Hes1, and YAP/TAZ, while under hypoxia its translation switches to an IRES-dependent mechanism, and post-transcriptionally the OTUD3/ZFP36 axis targets VEGF-C mRNA for degradation [PMID:18359770, PMID:22466647, PMID:19934313, PMID:24388748, PMID:34853315, PMID:32796823]. Meningeal lymphatic growth induced by VEGF-C enhances cerebrospinal fluid drainage and confers neuroprotection against ischemic stroke in mice [PMID:38442272]."},"prefetch_data":{"uniprot":{"accession":"P49767","full_name":"Vascular endothelial growth factor C","aliases":["Flt4 ligand","Flt4-L","Vascular endothelial growth factor-related protein","VRP"],"length_aa":419,"mass_kda":46.9,"function":"Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P49767/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/VEGFC","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/VEGFC","total_profiled":1310},"omim":[{"mim_id":"618335","title":"LONG INTERGENIC NONCODING RNA 958; LINC00958","url":"https://www.omim.org/entry/618335"},{"mim_id":"615907","title":"LYMPHATIC MALFORMATION 4; LMPHM4","url":"https://www.omim.org/entry/615907"},{"mim_id":"613480","title":"LYMPHATIC MALFORMATION 3; LMPHM3","url":"https://www.omim.org/entry/613480"},{"mim_id":"612753","title":"COLLAGEN AND CALCIUM-BINDING EGF DOMAIN-CONTAINING PROTEIN 1; CCBE1","url":"https://www.omim.org/entry/612753"},{"mim_id":"611944","title":"LYMPHATIC MALFORMATION 2; LMPHM2","url":"https://www.omim.org/entry/611944"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/VEGFC"},"hgnc":{"alias_symbol":["VRP","VEGF-C"],"prev_symbol":[]},"alphafold":{"accession":"P49767","domains":[{"cath_id":"2.10.90.10","chopping":"133-222","consensus_level":"high","plddt":92.7143,"start":133,"end":222},{"cath_id":"-","chopping":"283-345","consensus_level":"medium","plddt":79.3911,"start":283,"end":345},{"cath_id":"-","chopping":"391-419","consensus_level":"medium","plddt":75.1717,"start":391,"end":419}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49767","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49767-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49767-F1-predicted_aligned_error_v6.png","plddt_mean":73.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=VEGFC","jax_strain_url":"https://www.jax.org/strain/search?query=VEGFC"},"sequence":{"accession":"P49767","fasta_url":"https://rest.uniprot.org/uniprotkb/P49767.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49767/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49767"}},"corpus_meta":[{"pmid":"9233800","id":"PMC_9233800","title":"Proteolytic processing regulates receptor specificity and activity of VEGF-C.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9233800","citation_count":637,"is_preprint":false},{"pmid":"10329591","id":"PMC_10329591","title":"VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10329591","citation_count":478,"is_preprint":false},{"pmid":"22832193","id":"PMC_22832193","title":"VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics.","date":"2012","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/22832193","citation_count":288,"is_preprint":false},{"pmid":"16816121","id":"PMC_16816121","title":"Functional interaction of VEGF-C and VEGF-D with neuropilin receptors.","date":"2006","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/16816121","citation_count":237,"is_preprint":false},{"pmid":"12618526","id":"PMC_12618526","title":"VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12618526","citation_count":211,"is_preprint":false},{"pmid":"12397087","id":"PMC_12397087","title":"Therapeutic lymphangiogenesis with human recombinant VEGF-C.","date":"2002","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12397087","citation_count":200,"is_preprint":false},{"pmid":"16876204","id":"PMC_16876204","title":"Secondary lymphedema in the mouse tail: Lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9.","date":"2006","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/16876204","citation_count":189,"is_preprint":false},{"pmid":"22967508","id":"PMC_22967508","title":"Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22967508","citation_count":178,"is_preprint":false},{"pmid":"11687953","id":"PMC_11687953","title":"VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression.","date":"2001","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11687953","citation_count":177,"is_preprint":false},{"pmid":"12782675","id":"PMC_12782675","title":"The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12782675","citation_count":175,"is_preprint":false},{"pmid":"26459520","id":"PMC_26459520","title":"VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption.","date":"2015","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26459520","citation_count":172,"is_preprint":false},{"pmid":"11477575","id":"PMC_11477575","title":"Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11477575","citation_count":166,"is_preprint":false},{"pmid":"15590642","id":"PMC_15590642","title":"The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15590642","citation_count":158,"is_preprint":false},{"pmid":"16570043","id":"PMC_16570043","title":"COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16570043","citation_count":141,"is_preprint":false},{"pmid":"10600689","id":"PMC_10600689","title":"Current biology of VEGF-B and VEGF-C.","date":"1999","source":"Current opinion in biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/10600689","citation_count":133,"is_preprint":false},{"pmid":"16782443","id":"PMC_16782443","title":"VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival.","date":"2006","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/16782443","citation_count":131,"is_preprint":false},{"pmid":"11437102","id":"PMC_11437102","title":"Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer.","date":"2001","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/11437102","citation_count":119,"is_preprint":false},{"pmid":"11090062","id":"PMC_11090062","title":"VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11090062","citation_count":117,"is_preprint":false},{"pmid":"21904903","id":"PMC_21904903","title":"PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer.","date":"2011","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21904903","citation_count":113,"is_preprint":false},{"pmid":"11056103","id":"PMC_11056103","title":"Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta.","date":"2000","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/11056103","citation_count":108,"is_preprint":false},{"pmid":"22466647","id":"PMC_22466647","title":"SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/22466647","citation_count":108,"is_preprint":false},{"pmid":"24388748","id":"PMC_24388748","title":"Hypoxia induces VEGF-C expression in metastatic tumor cells via a HIF-1α-independent translation-mediated mechanism.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24388748","citation_count":105,"is_preprint":false},{"pmid":"15890974","id":"PMC_15890974","title":"Overexpression of VEGF-C causes transient lymphatic hyperplasia but not increased lymphangiogenesis in regenerating skin.","date":"2005","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/15890974","citation_count":92,"is_preprint":false},{"pmid":"9264375","id":"PMC_9264375","title":"Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia.","date":"1997","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9264375","citation_count":84,"is_preprint":false},{"pmid":"32513927","id":"PMC_32513927","title":"Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32513927","citation_count":81,"is_preprint":false},{"pmid":"25142796","id":"PMC_25142796","title":"SIX1 promotes tumor lymphangiogenesis by coordinating TGFβ signals that increase expression of VEGF-C.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25142796","citation_count":81,"is_preprint":false},{"pmid":"32473243","id":"PMC_32473243","title":"MiR-182-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-C.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32473243","citation_count":77,"is_preprint":false},{"pmid":"33299122","id":"PMC_33299122","title":"VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33299122","citation_count":77,"is_preprint":false},{"pmid":"11291931","id":"PMC_11291931","title":"Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer.","date":"2001","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/11291931","citation_count":75,"is_preprint":false},{"pmid":"18359770","id":"PMC_18359770","title":"VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18359770","citation_count":73,"is_preprint":false},{"pmid":"23695550","id":"PMC_23695550","title":"VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23695550","citation_count":72,"is_preprint":false},{"pmid":"34773968","id":"PMC_34773968","title":"ADSCs enhance VEGFR3-mediated lymphangiogenesis via METTL3-mediated VEGF-C m6A modification to improve wound healing of diabetic foot ulcers.","date":"2021","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/34773968","citation_count":69,"is_preprint":false},{"pmid":"22112321","id":"PMC_22112321","title":"Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-β1 inhibition.","date":"2011","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22112321","citation_count":67,"is_preprint":false},{"pmid":"16523449","id":"PMC_16523449","title":"Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas.","date":"2006","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16523449","citation_count":67,"is_preprint":false},{"pmid":"29939339","id":"PMC_29939339","title":"VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.","date":"2018","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29939339","citation_count":65,"is_preprint":false},{"pmid":"23874750","id":"PMC_23874750","title":"Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23874750","citation_count":63,"is_preprint":false},{"pmid":"29620526","id":"PMC_29620526","title":"VEGF-C promotes the development of lymphatics in bone and bone loss.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/29620526","citation_count":62,"is_preprint":false},{"pmid":"32544090","id":"PMC_32544090","title":"S1PR1 regulates the quiescence of lymphatic vessels by inhibiting laminar shear stress-dependent VEGF-C signaling.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32544090","citation_count":59,"is_preprint":false},{"pmid":"38442272","id":"PMC_38442272","title":"VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model.","date":"2024","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38442272","citation_count":58,"is_preprint":false},{"pmid":"33004630","id":"PMC_33004630","title":"Extracellular vesicle-associated VEGF-C promotes lymphangiogenesis and immune cells infiltration in endometriosis.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33004630","citation_count":58,"is_preprint":false},{"pmid":"28526302","id":"PMC_28526302","title":"An Important Role of VEGF-C in Promoting Lymphedema Development.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28526302","citation_count":58,"is_preprint":false},{"pmid":"19828679","id":"PMC_19828679","title":"The balance of autocrine VEGF-A and VEGF-C determines podocyte survival.","date":"2009","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19828679","citation_count":57,"is_preprint":false},{"pmid":"32796823","id":"PMC_32796823","title":"Distinct fibroblast subsets regulate lacteal integrity through YAP/TAZ-induced VEGF-C in intestinal villi.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32796823","citation_count":55,"is_preprint":false},{"pmid":"16247658","id":"PMC_16247658","title":"Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer.","date":"2005","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16247658","citation_count":55,"is_preprint":false},{"pmid":"12861060","id":"PMC_12861060","title":"Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression.","date":"2003","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/12861060","citation_count":54,"is_preprint":false},{"pmid":"32513642","id":"PMC_32513642","title":"Phase 1 LymfactinⓇ Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema.","date":"2020","source":"Journal of plastic, reconstructive & aesthetic surgery : JPRAS","url":"https://pubmed.ncbi.nlm.nih.gov/32513642","citation_count":54,"is_preprint":false},{"pmid":"15897888","id":"PMC_15897888","title":"Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15897888","citation_count":52,"is_preprint":false},{"pmid":"34853315","id":"PMC_34853315","title":"Nicotine-mediated OTUD3 downregulation inhibits VEGF-C mRNA decay to promote lymphatic metastasis of human esophageal cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34853315","citation_count":51,"is_preprint":false},{"pmid":"23784694","id":"PMC_23784694","title":"Acidic pH via NF-κB favours VEGF-C expression in human melanoma cells.","date":"2013","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/23784694","citation_count":51,"is_preprint":false},{"pmid":"31562136","id":"PMC_31562136","title":"Hemostasis stimulates lymphangiogenesis through release and activation of VEGFC.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/31562136","citation_count":50,"is_preprint":false},{"pmid":"31390756","id":"PMC_31390756","title":"Cancer-Derived VEGF-C Increases Chemokine Production in Lymphatic Endothelial Cells to Promote CXCR2-Dependent Cancer Invasion and MDSC Recruitment.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31390756","citation_count":50,"is_preprint":false},{"pmid":"32616854","id":"PMC_32616854","title":"Increased levels of VEGF-C and macrophage infiltration in lipedema patients without changes in lymphatic vascular morphology.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32616854","citation_count":49,"is_preprint":false},{"pmid":"14760756","id":"PMC_14760756","title":"Expression and significance of VEGF-C and FLT-4 in gastric cancer.","date":"2004","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/14760756","citation_count":48,"is_preprint":false},{"pmid":"25752543","id":"PMC_25752543","title":"Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble splice form.","date":"2015","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/25752543","citation_count":46,"is_preprint":false},{"pmid":"19934313","id":"PMC_19934313","title":"Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19934313","citation_count":46,"is_preprint":false},{"pmid":"24585459","id":"PMC_24585459","title":"VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24585459","citation_count":46,"is_preprint":false},{"pmid":"17351086","id":"PMC_17351086","title":"VEGF-C is associated with lymphatic status and invasion in oral cancer.","date":"2007","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17351086","citation_count":45,"is_preprint":false},{"pmid":"27345723","id":"PMC_27345723","title":"Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27345723","citation_count":45,"is_preprint":false},{"pmid":"19302023","id":"PMC_19302023","title":"Therapeutic responses to exogenous VEGF-C administration in experimental lymphedema: immunohistochemical and molecular characterization.","date":"2009","source":"Lymphatic research and biology","url":"https://pubmed.ncbi.nlm.nih.gov/19302023","citation_count":44,"is_preprint":false},{"pmid":"16525158","id":"PMC_16525158","title":"VEGF-C promotes survival in podocytes.","date":"2006","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16525158","citation_count":44,"is_preprint":false},{"pmid":"21482472","id":"PMC_21482472","title":"VEGF-C promotes the development of esophageal cancer via regulating CNTN-1 expression.","date":"2011","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/21482472","citation_count":41,"is_preprint":false},{"pmid":"19734356","id":"PMC_19734356","title":"VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B.","date":"2009","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19734356","citation_count":40,"is_preprint":false},{"pmid":"23761820","id":"PMC_23761820","title":"Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma.","date":"2013","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23761820","citation_count":39,"is_preprint":false},{"pmid":"22562155","id":"PMC_22562155","title":"Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients.","date":"2012","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22562155","citation_count":38,"is_preprint":false},{"pmid":"24337460","id":"PMC_24337460","title":"Overexpression of VEGF-C attenuates chronic high salt intake-induced left ventricular maladaptive remodeling in spontaneously hypertensive rats.","date":"2013","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24337460","citation_count":37,"is_preprint":false},{"pmid":"23076721","id":"PMC_23076721","title":"Induced lymphatic sinus hyperplasia in sentinel lymph nodes by VEGF-C as the earliest premetastatic indicator.","date":"2012","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23076721","citation_count":37,"is_preprint":false},{"pmid":"30554564","id":"PMC_30554564","title":"VEGF-C and Mortality in Patients With Suspected or Known Coronary Artery Disease.","date":"2018","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/30554564","citation_count":37,"is_preprint":false},{"pmid":"30518687","id":"PMC_30518687","title":"Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30518687","citation_count":36,"is_preprint":false},{"pmid":"27166194","id":"PMC_27166194","title":"CCL5 promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-507 in human chondrosarcoma cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27166194","citation_count":36,"is_preprint":false},{"pmid":"18679715","id":"PMC_18679715","title":"The role of VEGF-C staining in predicting regional metastasis in melanoma.","date":"2008","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18679715","citation_count":36,"is_preprint":false},{"pmid":"27343251","id":"PMC_27343251","title":"Critical requirement of VEGF-C in transition to fetal erythropoiesis.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27343251","citation_count":35,"is_preprint":false},{"pmid":"30378108","id":"PMC_30378108","title":"VEGF-C attenuates renal damage in salt-sensitive hypertension.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30378108","citation_count":34,"is_preprint":false},{"pmid":"12388793","id":"PMC_12388793","title":"VEGF-C mediates cyclic pressure-induced endothelial cell proliferation.","date":"2002","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/12388793","citation_count":33,"is_preprint":false},{"pmid":"29218079","id":"PMC_29218079","title":"VEGF-C mediated enhancement of lymphatic drainage reduces intestinal inflammation by regulating IL-9/IL-17 balance and improving gut microbiota in experimental chronic colitis.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/29218079","citation_count":33,"is_preprint":false},{"pmid":"20652010","id":"PMC_20652010","title":"CXCL7-Mediated Stimulation of Lymphangiogenic Factors VEGF-C, VEGF-D in Human Breast Cancer Cells.","date":"2010","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20652010","citation_count":32,"is_preprint":false},{"pmid":"27939650","id":"PMC_27939650","title":"The increased number of tumor-associated macrophage is associated with overexpression of VEGF-C, plays an important role in Kazakh ESCC invasion and metastasis.","date":"2016","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27939650","citation_count":32,"is_preprint":false},{"pmid":"24989178","id":"PMC_24989178","title":"Radiation-induced VEGF-C expression and endothelial cell proliferation in lung cancer.","date":"2014","source":"Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]","url":"https://pubmed.ncbi.nlm.nih.gov/24989178","citation_count":32,"is_preprint":false},{"pmid":"20830783","id":"PMC_20830783","title":"COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer.","date":"2010","source":"Anatomical record (Hoboken, N.J. : 2007)","url":"https://pubmed.ncbi.nlm.nih.gov/20830783","citation_count":31,"is_preprint":false},{"pmid":"16964283","id":"PMC_16964283","title":"RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16964283","citation_count":31,"is_preprint":false},{"pmid":"38211648","id":"PMC_38211648","title":"DHCR7 promotes lymph node metastasis in cervical cancer through cholesterol reprogramming-mediated activation of the KANK4/PI3K/AKT axis and VEGF-C secretion.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38211648","citation_count":30,"is_preprint":false},{"pmid":"14980429","id":"PMC_14980429","title":"Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA.","date":"2004","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/14980429","citation_count":27,"is_preprint":false},{"pmid":"25826569","id":"PMC_25826569","title":"The VrrA sRNA controls a stationary phase survival factor Vrp of Vibrio cholerae.","date":"2015","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/25826569","citation_count":25,"is_preprint":false},{"pmid":"25637798","id":"PMC_25637798","title":"Ischemic tolerance is associated with VEGF-C and VEGFR-3 signaling in the mouse hippocampus.","date":"2015","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25637798","citation_count":24,"is_preprint":false},{"pmid":"26573417","id":"PMC_26573417","title":"MicroRNA-101 induces apoptosis in cisplatin-resistant gastric cancer cells by targeting VEGF-C.","date":"2015","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26573417","citation_count":23,"is_preprint":false},{"pmid":"21565926","id":"PMC_21565926","title":"Exogenous VEGF-C augments the efficacy of therapeutic lymphangiogenesis induced by allogenic bone marrow stromal cells in a rabbit model of limb secondary lymphedema.","date":"2011","source":"Japanese journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21565926","citation_count":23,"is_preprint":false},{"pmid":"31739210","id":"PMC_31739210","title":"Long Noncoding RNA ASLNC07322 Functions in VEGF-C Expression Regulated by Smad4 during Colon Cancer Metastasis.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31739210","citation_count":23,"is_preprint":false},{"pmid":"36766814","id":"PMC_36766814","title":"Promotion of Lymphangiogenesis by Targeted Delivery of VEGF-C Improves Diabetic Wound Healing.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36766814","citation_count":22,"is_preprint":false},{"pmid":"22607367","id":"PMC_22607367","title":"Survivin regulates the expression of VEGF-C in lymphatic metastasis of breast cancer.","date":"2012","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22607367","citation_count":22,"is_preprint":false},{"pmid":"27553977","id":"PMC_27553977","title":"Total saponins of panaxnotoginseng promotes lymphangiogenesis by activation VEGF-C expression of lymphatic endothelial cells.","date":"2016","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27553977","citation_count":22,"is_preprint":false},{"pmid":"16808669","id":"PMC_16808669","title":"Vascular endothelial growth factor-C (VEGF-C) expression in normal human tissues.","date":"2006","source":"Lymphatic research and biology","url":"https://pubmed.ncbi.nlm.nih.gov/16808669","citation_count":22,"is_preprint":false},{"pmid":"27074165","id":"PMC_27074165","title":"Promoting inflammatory lymphangiogenesis by vascular endothelial growth factor-C (VEGF-C) aggravated intestinal inflammation in mice with experimental acute colitis.","date":"2016","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/27074165","citation_count":21,"is_preprint":false},{"pmid":"30289073","id":"PMC_30289073","title":"VEGFR2 and VEGF-C Suppresses the Epithelial-Mesenchymal Transition Via YAP in Retinal Pigment Epithelial Cells.","date":"2018","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30289073","citation_count":20,"is_preprint":false},{"pmid":"21343305","id":"PMC_21343305","title":"Lymphatic endothelial heparan sulfate deficiency results in altered growth responses to vascular endothelial growth factor-C (VEGF-C).","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21343305","citation_count":20,"is_preprint":false},{"pmid":"28591727","id":"PMC_28591727","title":"VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28591727","citation_count":20,"is_preprint":false},{"pmid":"31015298","id":"PMC_31015298","title":"Hes1 attenuates type I IFN responses via VEGF-C and WDFY1.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31015298","citation_count":19,"is_preprint":false},{"pmid":"21111670","id":"PMC_21111670","title":"Silencing Id-1 inhibits lymphangiogenesis through down-regulation of VEGF-C in oral squamous cell carcinoma.","date":"2010","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21111670","citation_count":19,"is_preprint":false},{"pmid":"34194927","id":"PMC_34194927","title":"Steroids Enable Mesenchymal Stromal Cells to Promote CD8+ T Cell Proliferation Via VEGF-C.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34194927","citation_count":18,"is_preprint":false},{"pmid":"19141404","id":"PMC_19141404","title":"Vascular endothelial growth factor (VEGF)-C - a potent risk factor in children diagnosed with stadium 4 neuroblastoma.","date":"2008","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/19141404","citation_count":18,"is_preprint":false},{"pmid":"24144865","id":"PMC_24144865","title":"VEGF-C in non-small cell lung cancer: meta-analysis.","date":"2013","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24144865","citation_count":17,"is_preprint":false},{"pmid":"19685508","id":"PMC_19685508","title":"Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.","date":"2009","source":"Anatomical record (Hoboken, N.J. : 2007)","url":"https://pubmed.ncbi.nlm.nih.gov/19685508","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52301,"output_tokens":8230,"usd":0.140177},"stage2":{"model":"claude-opus-4-6","input_tokens":11992,"output_tokens":5150,"usd":0.283065},"total_usd":0.423242,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Stepwise proteolytic processing of the VEGF-C precursor generates several forms with progressively increased activity toward VEGFR-3; only the fully processed (mature) form can activate VEGFR-2. Mature VEGF-C binds VEGFR-3 (Kd=135 pM) and VEGFR-2 (Kd=410 pM), increases vascular permeability, and promotes endothelial cell migration and proliferation. Unlike other PDGF/VEGF family members, mature VEGF-C forms predominantly non-covalent homodimers.\",\n      \"method\": \"Recombinant protein production in yeast, receptor-binding assays, receptor phosphorylation assays, endothelial cell proliferation/migration assays, vascular permeability assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding, mutagenesis-equivalent processing studies, multiple orthogonal functional assays; highly cited foundational paper\",\n      \"pmids\": [\"9233800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The proprotein convertases furin, PC5, and PC7 cleave proVEGF-C at the dibasic motif HSIIRR↓SL to generate mature VEGF-C. Mutation of this cleavage site (HSIIRR→HSIISS) blocks processing and abolishes VEGF-C-induced angiogenesis, lymphangiogenesis, and tumor growth in vivo, demonstrating that proteolytic processing by PCs is required for VEGF-C bioactivity.\",\n      \"method\": \"Cotransfection in furin-deficient LoVo cells, in vitro fluorogenic peptide cleavage assay, site-directed mutagenesis of cleavage site, subcutaneous tumor implantation in nude mice\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with mutagenesis and in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"12782675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"VEGF-C and VEGF-D directly bind neuropilin-2 (NP2) in a heparin-independent manner (VEGF-C) or heparin-dependent manner (VEGF-D). Upon VEGF-C or VEGF-D stimulation, NP2 co-internalizes with VEGFR-3 into endocytic vesicles of lymphatic endothelial cells, and NP2 co-precipitates with VEGFR-3, indicating NP2 participates in an active signaling complex with VEGFR-3.\",\n      \"method\": \"In vitro binding studies, domain-mapping experiments, co-internalization imaging, co-immunoprecipitation\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding and co-IP with functional co-internalization evidence; multiple orthogonal approaches\",\n      \"pmids\": [\"16816121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"VEGF-C (and VEGF-D) are direct ligands for the integrin α9β1. Cells expressing α9β1 adhere to and migrate on VEGF-C in a concentration-dependent, antibody-blockable manner; recombinant VEGF-C binds purified α9β1 integrin in a dose- and cation-dependent solid-phase assay; in cells lacking cognate VEGF receptors, VEGF-C induces α9β1-dependent ERK and paxillin phosphorylation.\",\n      \"method\": \"Cell adhesion and migration assays with α9β1-transfected cells, function-blocking antibody, solid-phase binding with purified integrin, signaling assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding to purified protein, functional cell assays, signaling readouts; multiple orthogonal methods\",\n      \"pmids\": [\"15590642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of the VEGF-C C-terminus in complex with the ligand-binding domains (b1) of neuropilin-2 reveals that a cryptic Nrp2-binding motif is exposed only upon C-terminal proteolytic maturation of VEGF-C. The endogenous secreted splice form s9Nrp2 forms a stable dimer that potently inhibits VEGF-C/Nrp2 binding and downstream cellular signaling.\",\n      \"method\": \"X-ray crystallography, biochemical binding assays, cell-based signaling assays\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation; demonstrates structural mechanism of proteolysis-regulated Nrp2 binding\",\n      \"pmids\": [\"25752543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"VEGF-C signals through both VEGFR-2 and VEGFR-3 during vasculogenesis and hematopoiesis. In VEGFR-3-deficient embryos, excess VEGF-C signals through VEGFR-2 and disturbs vasculogenesis and hematopoiesis; trapping VEGF-C with VEGFR-3-Fc in these embryos rescues vascular bed formation and partially rescues hematopoiesis, indicating that VEGFR-3 binding regulates the available pool of VEGF-C for VEGFR-2 signaling.\",\n      \"method\": \"Para-aortic splanchnopleural mesoderm coculture with stromal cells, soluble receptor competitor proteins, VEGFR-3 knockout embryos, rescue experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with knockout embryos and receptor-trap rescue; multiple orthogonal genetic and pharmacological tools\",\n      \"pmids\": [\"11090062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RANKL stimulates osteoclasts and their precursors to express and secrete VEGF-C through an NF-κB-dependent mechanism (reduced in NF-κBp50/p52 double-knockout cells or with NF-κB inhibitor). VEGF-C then acts as an autocrine factor via VEGFR-3 on osteoclasts: it stimulates Src phosphorylation and enhances bone resorption, an effect blocked by VEGFR3:Fc or in Src-knockout osteoclasts.\",\n      \"method\": \"Real-time RT-PCR, Western blot, immunostaining, osteoclastogenesis and pit resorption assays, NF-κB inhibition, knockout osteoclasts, receptor-blocking fusion protein\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic loss-of-function models, receptor-specific blocking, functional readout; strong mechanistic evidence\",\n      \"pmids\": [\"18359770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"VEGF-C is required for maintenance of intestinal lymphatic vessels (lacteals) in adult mice; conditional Vegfc deletion leads to lacteal atrophy, defective dietary lipid absorption, and increased fecal excretion of cholesterol and fatty acids. VEGF-C is expressed by a subset of smooth muscle cells adjacent to the lacteals. Deletion also causes resistance to high-fat diet-induced obesity.\",\n      \"method\": \"Conditional Vegfc gene deletion in adult mice, histology, lipid absorption assays, fecal fat measurement, high-fat diet challenge\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional knockout with specific functional phenotype (lipid absorption) and defined cellular source\",\n      \"pmids\": [\"26459520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VEGF-C plays a critical role in the transition from primitive to definitive (fetal liver) erythropoiesis. Vegfc deletion at E7.5 causes defective fetal erythropoiesis: anemia, lack of enucleated red blood cells, and reduced macrophage and erythroid cell numbers in fetal liver due to decreased proliferation and increased apoptosis. VEGF-C loss reduces α4-integrin expression on erythro-myeloid progenitors, impairing their colonization of the fetal liver.\",\n      \"method\": \"Conditional Vegfc gene deletion in mouse embryos, flow cytometry, colony assays, α4-integrin expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional knockout with mechanistic cellular readout (integrin-dependent progenitor migration) and multiple hematopoietic phenotypes\",\n      \"pmids\": [\"27343251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"VEGF-C (and VEGF-D) are cleaved and activated by thrombin and plasmin, serine proteases generated during hemostasis and wound healing. Platelets accelerate lymphatic growth after injury in vivo in a VEGF-C-dependent manner (but not VEGF-D-dependent), establishing a molecular link between hemostasis/platelet activation and lymphangiogenesis.\",\n      \"method\": \"In vitro cleavage assays with thrombin and plasmin, tail-wounding assay in mice, genetic studies with platelet-specific deletion, lymphangiogenesis quantification\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro biochemical cleavage assays combined with in vivo genetic studies; multiple orthogonal approaches\",\n      \"pmids\": [\"31562136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"VEGF-C binds to heparan sulfate on lymphatic endothelial cells; heparin interference or heparinase treatment reduces VEGF-C-induced ERK1/2 and VEGFR-3 phosphorylation. Silencing of lymphatic Ndst1 (a heparan sulfate biosynthetic enzyme) inhibits VEGF-C-mediated ERK1/2 activation, abrogates cell-surface VEGFR-3-dependent VEGF-C binding, and reduces cell growth, migration, and collagen matrix sprouting in response to VEGF-C.\",\n      \"method\": \"Heparan sulfate binding assays, heparinase treatment, siRNA knockdown of Ndst1, phosphorylation assays, scratch migration assays, ex vivo sprouting in collagen matrix\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple loss-of-function approaches (pharmacological and genetic) with signaling and functional readouts\",\n      \"pmids\": [\"21343305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FGF-2 and VEGF-C collaboratively promote lymphangiogenesis; VEGFR-3-mediated signaling is required for lymphatic tip cell formation in both FGF-2- and VEGF-C-induced lymphangiogenesis. A VEGFR-3-specific neutralizing antibody markedly inhibits FGF-2-induced lymphangiogenesis, placing VEGFR-3 downstream of FGF-2/FGFR-1 for tip cell formation.\",\n      \"method\": \"Mouse cornea lymphangiogenesis assay, VEGFR-3-neutralizing antibody, in vivo coimplantation, tumor metastasis models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo epistasis with neutralizing antibody; single lab\",\n      \"pmids\": [\"22967508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"COX-2 promotes VEGF-C synthesis in breast cancer cells via prostaglandin E2 (PGE2) signaling through EP1 and EP4 receptors; EP1 and EP4 antagonists inhibit VEGF-C production. VEGF-C secretion also requires Her-2/neu, Src, and p38 MAPK kinase activities, as inhibitors of these kinases block VEGF-C secretion.\",\n      \"method\": \"COX-2 siRNA knockdown, COX inhibitors, EP receptor antagonists, kinase inhibitors, ELISA for VEGF-C secretion, LYVE-1 immunostaining in breast cancer tissues\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological pathway dissection with multiple inhibitors; single lab with moderate mechanistic depth\",\n      \"pmids\": [\"16570043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The transcription factor SIX1 directly induces transcription of VEGF-C; SIX1-induced VEGF-C is required for peritumoral and intratumoral lymphangiogenesis and lymphatic metastasis of breast cancer cells in immunocompromised mice.\",\n      \"method\": \"SIX1 overexpression and knockdown in human breast cancer cells, mouse xenograft models, lymphangiogenesis quantification, VEGF-C rescue experiments\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain/loss of function with VEGF-C rescue experiment; single lab\",\n      \"pmids\": [\"22466647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Hypoxia reduces VEGF-C transcription and cap-dependent translation via upregulation of hypophosphorylated 4E-BP1, but induces VEGF-C translation through an internal ribosome entry site (IRES)-dependent, HIF-1α-independent mechanism. IRES-dependent VEGF-C translation is higher in metastasizing tumor cells within lymph nodes (severely hypoxic) than in primary tumors.\",\n      \"method\": \"IRES reporter assays, 4E-BP1 phosphorylation analysis, HIF-1α knockdown, cap-dependent vs. IRES-dependent translation assays, in vivo tumor/lymph node comparison\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — IRES reporter assays combined with genetic knockdown and in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"24388748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Androgens regulate VEGF-C expression: androgen deprivation in LNCaP prostate cancer cells activates the small GTPase RalA (via elevated reactive oxygen species), and RalA activation leads to VEGF-C upregulation. The FOXO-1 transcription factor (activated by SIRT-1 downstream of reduced IGF-IR signaling) also mediates VEGF-C transcriptional upregulation upon androgen withdrawal.\",\n      \"method\": \"RalA activation assays, ROS measurement, RalA dominant-negative/knockdown, FOXO-1 siRNA, VEGF-C mRNA/protein measurement\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic and pharmacological pathway dissection in cell lines; single lab\",\n      \"pmids\": [\"16964283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Nicotine downregulates the deubiquitinase OTUD3, which normally stabilizes the mRNA-binding protein ZFP36 by inhibiting FBXW7-mediated K48-linked polyubiquitination. ZFP36 binds the VEGF-C 3'-UTR and recruits an RNA-degrading complex to induce VEGF-C mRNA decay; loss of OTUD3/ZFP36 leads to VEGF-C mRNA stabilization and increased VEGF-C production, promoting lymphatic metastasis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, RNA immunoprecipitation, RNA pulldown, mRNA stability assays, in vivo metastasis models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic chain established by RIP, RNA pulldown, ubiquitination assays, and in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"34853315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"VEGF-C is transported by extracellular vesicles (EVs) from endometriotic cells to lymphatic endothelial cells where it enhances lymphangiogenic capacity. The orphan nuclear receptor COUP-TFII negatively regulates VEGF-C expression; proinflammatory cytokines suppress COUP-TFII, thereby inducing VEGF-C overexpression.\",\n      \"method\": \"Extracellular vesicle isolation and functional assays, COUP-TFII knockdown, cytokine treatment, autotransplanted mouse model of endometriosis, lenvatinib treatment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — EV-mediated transfer demonstrated functionally; COUP-TFII regulation shown by knockdown; single lab\",\n      \"pmids\": [\"33004630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PIK3CA(H1047R)-driven lymphatic malformations grow in a VEGF-C-dependent manner; combined inhibition of VEGF-C (blocking VEGF-C/VEGFR3 signaling) and mTOR (downstream of PI3K) with rapamycin promotes regression of microcystic lymphatic malformations, whereas neither treatment alone is sufficient.\",\n      \"method\": \"Mouse model of PIK3CA(H1047R)-driven lymphatic malformations, VEGF-C inhibition, rapamycin treatment, epistasis by combined pharmacological blockade\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic mouse model with pharmacological epistasis; single lab but rigorous in vivo design\",\n      \"pmids\": [\"32513927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In intestinal villi, YAP/TAZ activity in PDGFRβ+ interstitial stromal cells drives VEGF-C secretion to maintain lacteal integrity and dietary fat uptake. Mechanical or osmotic stress regulates YAP/TAZ-dependent VEGF-C secretion in these cells; single-cell RNA sequencing identified distinct fibroblast subtypes near lacteals that upregulate Vegfc upon YAP/TAZ activation.\",\n      \"method\": \"Conditional YAP/TAZ hyperactivation or depletion in PDGFRβ+ cells, single-cell RNA sequencing, VEGF-C ELISA, lacteal morphology and fat uptake assays, mechanical/osmotic stress experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional genetic models with scRNA-seq and functional phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"32796823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"VEGF-C regulates capillary stabilization through paracrine induction of PDGF-B expression. In ischemic hindlimb, VEGFR-3 blockade not only diminishes lymphangiogenesis but also causes capillary dilation with mural cell dissociation; VEGF-C and PDGF-B expression are mutually dependent (blocking either reduces expression of the other), placing VEGF-C upstream of PDGF-B-mediated vessel stabilization.\",\n      \"method\": \"VEGFR-3 neutralizing antibody in ischemic hindlimb model, FGF-2 adenoviral gene transfer, real-time RT-PCR, histology, limb salvage/blood flow assessment\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vivo pharmacological epistasis; single lab; indirect evidence for PDGF-B regulation\",\n      \"pmids\": [\"19734356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"VEGF-C promotes podocyte survival through an autocrine mechanism: ablation of VEGF-C or treatment with a VEGFR-2/-3 tyrosine kinase inhibitor reduces podocyte survival, and VEGF-C activates antiapoptotic PI3K/AKT and suppresses p38MAPK via VEGFR-2 (SU-5416 at VEGFR-1-specific concentration blocks VEGF-C survival effect, suggesting a VEGFR-1-containing complex may be involved).\",\n      \"method\": \"VEGF-C siRNA knockdown in human conditionally immortalized podocytes, cytotoxicity assays, kinase inhibitors (MAZ51, SU-5416), phosphorylation assays, intracellular calcium measurements, immunoprecipitation\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple pharmacological tools and siRNA in primary-like cells; single lab; receptor identity not fully resolved\",\n      \"pmids\": [\"16525158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"VEGF-C activates autocrine VEGFR-2 signaling in glioblastoma cells to promote cell survival and tumor growth; VEGF-C/VEGFR-2 interaction was detected by proximity ligation assay in surgical specimens. Targeting VEGF-C (but not bevacizumab, which targets VEGF-A) impairs glioblastoma tumor growth in vivo.\",\n      \"method\": \"RNA interference, proximity ligation assay, immunohistochemistry, patient-derived xenograft lines in vitro and in vivo\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNAi with in vivo validation and proximity ligation assay for endogenous interaction; single lab\",\n      \"pmids\": [\"29939339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"VEGF-C secreted by EMT breast cancer cells activates non-canonical GLI signaling in neighboring epithelial breast cancer cells via NRP2 (a VEGF-C receptor), promoting their proliferation, migration, invasion, and metastasis. This paracrine VEGF-C/NRP2/GLI axis can be disrupted by VEGF-C inhibition in EMT cells or NRP2 knockdown in epithelial cells.\",\n      \"method\": \"VEGF-C knockdown, NRP2 knockdown, GLI signaling assays, in vivo metastasis models, conditioned medium experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genetic loss-of-function with in vivo validation; single lab; NRP2 as VEGF-C receptor in this context\",\n      \"pmids\": [\"33299122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"S1PR1 in lymphatic endothelial cells antagonizes laminar shear stress-induced VEGF-C/VEGFR3 signaling to promote lymphatic vascular quiescence. S1pr1 loss in LECs induces lymphatic hypersprouting and hyperbranching that can be rescued by reducing Vegfr3 gene dosage in vivo, placing S1PR1 as a negative regulator upstream of VEGF-C/VEGFR3-driven sprouting.\",\n      \"method\": \"Conditional S1pr1 knockout in LECs, Vegfr3 genetic rescue, laminar shear stress assays, signaling assays, in vivo vascular phenotyping\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (double mutant rescue) with in vivo vascular phenotype; clean mechanistic pathway placement\",\n      \"pmids\": [\"32544090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Gonadotropins (LH, FSH) induce VEGF-C expression in ovarian cancer cells via LEDGF/p75, which binds a stress-response element in the VEGF-C promoter (confirmed by chromatin immunoprecipitation); FSH augments LEDGF/p75 binding to the VEGF-C promoter. LEDGF siRNA, GnRH antagonist, or mutation of the stress-response element suppresses gonadotropin-induced VEGF-C expression.\",\n      \"method\": \"Chromatin immunoprecipitation, LEDGF siRNA, GnRH antagonist (cetrorelix), promoter mutation, ovariectomy mouse model, VEGF-C mRNA and promoter activity assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms direct promoter binding; multiple genetic and pharmacological approaches; single lab\",\n      \"pmids\": [\"19934313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"VEGF-C, induced in mesenchymal stromal cells by steroids and TNFα, promotes CD8+ T cell proliferation via VEGFR-3 expressed on CD8+ T cells; VEGF-C augments PI3K/AKT signaling and downstream Cyclin D1 expression in CD8+ T cells. Blockade or genetic ablation of VEGFR3 in CD8+ T cells abolishes the VEGF-C-mediated immune-promoting effect.\",\n      \"method\": \"MSC-CD8+ T cell co-culture, VEGFR3 blockade antibody, conditional VEGFR3 knockout in T cells, PI3K/AKT signaling assays, in vivo GvHD model\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function of receptor in CD8+ T cells combined with signaling assays; single lab\",\n      \"pmids\": [\"34194927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Hes1, a transcription factor, directly binds and positively activates VEGF-C gene expression (genome-wide Hes1 occupancy analysis); elevated VEGF-C produced downstream of Hes1 attenuates TLR upstream signaling by inhibiting the adaptor WDFY1, thereby suppressing type I IFN production.\",\n      \"method\": \"Genome-wide ChIP-seq for Hes1 occupancy, Hes1 knockout mice, VEGF-C expression analysis, WDFY1 signaling assays, viral infection and lupus nephritis models\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq for direct binding combined with genetic knockout and functional immune phenotype; single lab\",\n      \"pmids\": [\"31015298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SIX1 cooperates with TGFβ/SMAD2/3 signaling to enhance VEGF-C expression in cervical cancer cells; SIX1 augments TGFβ-induced SMAD2/3 activation, and together they produce much higher VEGF-C than either alone. Increased VEGF-C from SIX1-expressing tumor cells promotes lymphatic endothelial cell migration and tube formation and counteracts TGFβ's direct inhibitory effects on LECs.\",\n      \"method\": \"SIX1 overexpression/knockdown, TGFβ treatment, SMAD2/3 phosphorylation assays, VEGF-C promoter/expression assays, LEC migration and tube formation assays, in vivo lymphangiogenesis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple cell-based epistasis experiments; single lab\",\n      \"pmids\": [\"25142796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Intracerebrospinal AAV-mediated VEGF-C overexpression enhances CSF drainage to deep cervical lymph nodes by promoting meningeal lymphatic vessel growth, upregulates neuroprotective signaling pathways, and reduces ischemic stroke injury in mice. Neuroprotective effects are lost upon cauterization of afferent lymphatics to the deep cervical lymph nodes, demonstrating that the effect is mediated through enhanced lymphatic drainage.\",\n      \"method\": \"AAV-mVEGF-C intracerebrospinal delivery, lymphatic cauterization, single-nucleus RNA sequencing, CSF drainage assays, ischemic stroke model (MRI, behavioral tests)\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic link established by lymphatic cauterization rescue experiment; multiple readouts; single lab\",\n      \"pmids\": [\"38442272\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VEGF-C is secreted as a precursor that undergoes stepwise proteolytic processing by proprotein convertases (furin, PC5, PC7) and serine proteases (thrombin, plasmin) to generate mature forms with progressively higher affinity for VEGFR-3 and, for the fully processed form, VEGFR-2; mature VEGF-C also binds co-receptors neuropilin-2 (via a cryptic, proteolysis-exposed motif engaging the Nrp2-b1 domain, as revealed by crystal structure) and integrin α9β1, and heparan sulfate facilitates VEGFR-3 engagement; through VEGFR-3 and VEGFR-2 signaling, VEGF-C drives lymphangiogenesis, blood vascular angiogenesis, lymphatic vessel maintenance (particularly intestinal lacteals), fetal erythropoiesis, podocyte survival, osteoclast bone resorption, and CD8+ T cell proliferation, while its expression is regulated transcriptionally by NF-κB, SIX1, LEDGF/p75, FOXO-1, COX-2/PGE2, Hes1, YAP/TAZ, and post-transcriptionally by IRES-dependent translation under hypoxia and by the OTUD3/ZFP36 mRNA-decay axis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"VEGF-C is a secreted lymphangiogenic and angiogenic growth factor that undergoes obligate stepwise proteolytic processing — by proprotein convertases (furin, PC5, PC7) and serine proteases (thrombin, plasmin) — to generate mature forms with progressively higher affinity for VEGFR-3 (Kd ~135 pM) and, for the fully processed form, VEGFR-2 (Kd ~410 pM); processing also exposes a cryptic neuropilin-2-binding motif whose structural basis has been defined by crystallography [PMID:9233800, PMID:12782675, PMID:31562136, PMID:25752543]. Mature VEGF-C additionally engages integrin α9β1 and heparan sulfate as co-receptors that facilitate VEGFR-3 signaling, and signals through PI3K/AKT and Src pathways to drive lymphangiogenesis, blood vascular angiogenesis, intestinal lacteal maintenance and dietary lipid absorption, fetal erythropoiesis, osteoclast-mediated bone resorption, podocyte survival, and CD8+ T cell proliferation [PMID:15590642, PMID:21343305, PMID:26459520, PMID:27343251, PMID:18359770, PMID:16525158, PMID:34194927]. VEGF-C transcription is driven by NF-κB, SIX1, LEDGF/p75, FOXO-1, Hes1, and YAP/TAZ, while under hypoxia its translation switches to an IRES-dependent mechanism, and post-transcriptionally the OTUD3/ZFP36 axis targets VEGF-C mRNA for degradation [PMID:18359770, PMID:22466647, PMID:19934313, PMID:24388748, PMID:34853315, PMID:32796823]. Meningeal lymphatic growth induced by VEGF-C enhances cerebrospinal fluid drainage and confers neuroprotection against ischemic stroke in mice [PMID:38442272].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing that VEGF-C bioactivity requires stepwise proteolytic maturation resolved how a single precursor generates forms with differential receptor selectivity — only the fully processed mature form activates VEGFR-2, while intermediates activate VEGFR-3 alone.\",\n      \"evidence\": \"Recombinant VEGF-C processing in yeast, receptor-binding/phosphorylation assays, endothelial proliferation/migration/permeability assays\",\n      \"pmids\": [\"9233800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the endogenous processing proteases was unknown\", \"Structural basis for receptor selectivity of different processed forms unresolved\", \"In vivo significance of differential receptor activation not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of furin, PC5, and PC7 as the proprotein convertases that cleave proVEGF-C at the HSIIRR motif — and demonstration that mutating this site abolishes in vivo angiogenesis and lymphangiogenesis — established that PC-mediated processing is the gateway to VEGF-C bioactivity.\",\n      \"evidence\": \"Enzymatic cleavage assays in furin-deficient cells, site-directed mutagenesis, tumor implantation in nude mice\",\n      \"pmids\": [\"12782675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional proteases contribute to VEGF-C activation in vivo remained open\", \"Tissue-specific regulation of PC access to proVEGF-C unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that VEGF-C signals through both VEGFR-3 and VEGFR-2 during embryonic vasculogenesis and hematopoiesis, with VEGFR-3 acting as a sink to regulate VEGF-C availability for VEGFR-2, established the dual-receptor signaling logic governing VEGF-C function in development.\",\n      \"evidence\": \"VEGFR-3-deficient embryo cultures, soluble VEGFR-3-Fc rescue, hematopoietic colony assays\",\n      \"pmids\": [\"11090062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream intracellular pathways distinguishing VEGFR-2 vs VEGFR-3 signaling in hematopoiesis unresolved\", \"Relative contribution of each receptor in different tissues unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Discovery of integrin α9β1 as a direct VEGF-C receptor that signals independently of VEGFR-2/VEGFR-3 expanded the receptor repertoire beyond tyrosine kinases and explained VEGF-C effects in VEGFR-negative cells.\",\n      \"evidence\": \"Solid-phase binding with purified integrin, adhesion/migration assays with α9β1-transfected cells, ERK/paxillin signaling in VEGFR-lacking cells\",\n      \"pmids\": [\"15590642\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context where α9β1 is the dominant VEGF-C receptor not defined\", \"Structural basis for VEGF-C/α9β1 interaction unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of neuropilin-2 as a VEGF-C co-receptor that co-internalizes with VEGFR-3 upon ligand stimulation established NRP2 as a component of the active lymphangiogenic signaling complex, and demonstration of VEGF-C's autocrine survival role in podocytes broadened its functions beyond vascular contexts.\",\n      \"evidence\": \"Binding assays, co-IP, co-internalization imaging for NRP2/VEGFR-3; siRNA, kinase inhibitors, and apoptosis assays in podocytes\",\n      \"pmids\": [\"16816121\", \"16525158\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism of NRP2/VEGF-C interaction not yet resolved\", \"Whether NRP2 modulates VEGFR-3 signaling quantitatively or qualitatively unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showing that RANKL induces VEGF-C expression via NF-κB in osteoclasts, which then signals autocrinally through VEGFR-3/Src to enhance bone resorption, established the first non-vascular autocrine loop for VEGF-C and linked it to skeletal homeostasis.\",\n      \"evidence\": \"NF-κBp50/p52 double-knockout osteoclasts, VEGFR3:Fc blocking, Src-knockout osteoclasts, pit resorption assays\",\n      \"pmids\": [\"18359770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether VEGF-C/VEGFR-3 signaling in osteoclasts is relevant in non-pathological bone remodeling unclear\", \"Downstream effectors beyond Src not mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Dissection of transcriptional regulators — LEDGF/p75 binding the VEGF-C promoter downstream of gonadotropins, and FOXO-1 mediating androgen withdrawal-induced VEGF-C — revealed context-dependent transcriptional control linking hormonal cues to lymphangiogenic output.\",\n      \"evidence\": \"ChIP for LEDGF/p75 at VEGF-C promoter, siRNA, GnRH antagonist; RalA activation assays, FOXO-1 knockdown in prostate cancer cells\",\n      \"pmids\": [\"19934313\", \"16964283\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether LEDGF/p75 and FOXO-1 cooperate or operate in distinct cellular contexts not tested\", \"Full promoter architecture and enhancer landscape of VEGF-C uncharacterized\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that heparan sulfate on lymphatic endothelial cells is required for VEGF-C binding to VEGFR-3 and for downstream ERK1/2 activation added a glycosaminoglycan co-receptor requirement to the VEGF-C signaling model.\",\n      \"evidence\": \"Heparinase treatment, Ndst1 siRNA knockdown, VEGFR-3 phosphorylation assays, sprouting assays in collagen matrices\",\n      \"pmids\": [\"21343305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific heparan sulfate modifications (sulfation patterns) that mediate VEGF-C interaction unknown\", \"Whether heparan sulfate requirement is shared across all VEGF-C target cell types not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"SIX1 was identified as a direct transcriptional activator of VEGF-C that drives tumor lymphangiogenesis and lymphatic metastasis, providing a molecular link between a developmental transcription factor and tumor-associated lymphatic remodeling.\",\n      \"evidence\": \"SIX1 overexpression/knockdown in breast cancer cells, VEGF-C rescue, xenograft lymphangiogenesis quantification\",\n      \"pmids\": [\"22466647\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SIX1 binds the VEGF-C promoter directly (ChIP) was not shown in this study\", \"Relevance to non-neoplastic lymphangiogenesis not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that hypoxia switches VEGF-C translation from cap-dependent to IRES-dependent (independent of HIF-1α) explained how VEGF-C protein production is sustained in severely hypoxic microenvironments such as tumor-draining lymph nodes.\",\n      \"evidence\": \"IRES reporter assays, 4E-BP1 phosphorylation analysis, HIF-1α knockdown, comparison of VEGF-C in primary tumors vs lymph node metastases\",\n      \"pmids\": [\"24388748\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"IRES trans-acting factors that mediate VEGF-C IRES activity unidentified\", \"Whether IRES-dependent translation is relevant in non-tumor hypoxia not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The crystal structure of the VEGF-C C-terminus bound to the NRP2-b1 domain revealed that proteolytic maturation exposes a cryptic NRP2-binding motif, providing the structural basis for how processing controls co-receptor engagement and offering a template for soluble NRP2-based inhibitors.\",\n      \"evidence\": \"X-ray crystallography, binding assays, cell-based signaling assays with soluble s9Nrp2 inhibitor\",\n      \"pmids\": [\"25752543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full ternary complex of VEGF-C/NRP2/VEGFR-3 not structurally resolved\", \"Whether the s9Nrp2 decoy has therapeutic utility in vivo not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Conditional Vegfc deletion in adult mice causing lacteal atrophy and defective lipid absorption proved that VEGF-C is continuously required for intestinal lymphatic maintenance, not only developmental lymphangiogenesis.\",\n      \"evidence\": \"Conditional Vegfc knockout in adult mice, histology, fecal fat measurements, high-fat diet challenge\",\n      \"pmids\": [\"26459520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The specific VEGFR (VEGFR-2 vs VEGFR-3) mediating lacteal maintenance not genetically dissected\", \"Whether VEGF-C from smooth muscle cells is the sole source or other cells contribute not excluded\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that embryonic Vegfc deletion blocks the transition from primitive to definitive erythropoiesis — via reduced α4-integrin on progenitors impairing fetal liver colonization — revealed an unexpected hematopoietic role for VEGF-C beyond vascular development.\",\n      \"evidence\": \"Conditional Vegfc deletion at E7.5, flow cytometry, colony assays, α4-integrin expression analysis\",\n      \"pmids\": [\"27343251\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether VEGF-C regulates α4-integrin directly or indirectly unresolved\", \"The receptor mediating this effect on erythro-myeloid progenitors not definitively identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of thrombin and plasmin as VEGF-C-activating proteases, and demonstration that platelets drive wound lymphangiogenesis via VEGF-C, established a molecular link between hemostasis and lymphatic repair.\",\n      \"evidence\": \"In vitro cleavage assays, platelet-specific genetic deletion, tail-wounding lymphangiogenesis quantification in mice\",\n      \"pmids\": [\"31562136\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of thrombin vs plasmin vs furin/PCs in wound healing not quantified\", \"Whether platelet-derived VEGF-C is pre-stored or de novo synthesized not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"ChIP-seq identification of Hes1 as a direct transcriptional activator of VEGF-C, coupled with the finding that VEGF-C attenuates TLR signaling by suppressing WDFY1, revealed an immunomodulatory arm of VEGF-C function.\",\n      \"evidence\": \"Genome-wide Hes1 ChIP-seq, Hes1 knockout mice, WDFY1 signaling analysis, viral infection and lupus nephritis models\",\n      \"pmids\": [\"31015298\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which VEGF-C inhibits WDFY1 not fully elucidated\", \"Whether this pathway operates in non-immune cell types unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Multiple 2020 studies converged on tissue-specific regulatory axes: YAP/TAZ in intestinal stromal cells drives VEGF-C for lacteal maintenance; S1PR1 in lymphatic endothelium antagonizes VEGF-C/VEGFR-3 to enforce vascular quiescence; and EV-mediated VEGF-C transport and COUP-TFII-dependent repression operate in endometriosis — collectively revealing that VEGF-C bioavailability is tuned by mechanosensitive, inflammatory, and vesicular mechanisms.\",\n      \"evidence\": \"Conditional YAP/TAZ models with scRNA-seq; conditional S1pr1 knockout with Vegfr3 genetic rescue; EV isolation and COUP-TFII knockdown in endometriosis models\",\n      \"pmids\": [\"32796823\", \"32544090\", \"33004630\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether YAP/TAZ regulation of VEGF-C extends to other organs not tested\", \"Mechanotransduction pathway connecting shear stress to S1PR1-mediated VEGFR-3 suppression incompletely defined\", \"COUP-TFII regulation confirmed in one disease context only\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery of the OTUD3/ZFP36 axis — where OTUD3 stabilizes ZFP36 to promote VEGF-C mRNA decay — established the first post-transcriptional regulatory circuit controlling VEGF-C abundance, and its disruption by nicotine explained increased lymphatic metastasis.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, RNA immunoprecipitation, RNA pulldown, mRNA stability assays, in vivo metastasis models\",\n      \"pmids\": [\"34853315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other ARE-binding proteins besides ZFP36 target VEGF-C mRNA not examined\", \"Generalizability beyond nicotine-exposed tumor context unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstration that VEGF-C promotes CD8+ T cell proliferation via VEGFR-3/PI3K/AKT/Cyclin D1 expanded VEGF-C biology into adaptive immunity, showing it is not exclusively a vascular growth factor.\",\n      \"evidence\": \"MSC-CD8+ T cell co-culture, conditional VEGFR3 knockout in T cells, PI3K/AKT signaling, GvHD model\",\n      \"pmids\": [\"34194927\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether VEGF-C/VEGFR-3 signaling on T cells operates during normal immune responses not established\", \"Interaction with other T cell co-stimulatory pathways not addressed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"AAV-mediated VEGF-C overexpression in the CNS promoted meningeal lymphatic growth and enhanced CSF drainage, reducing ischemic stroke injury — an effect abolished by lymphatic cauterization — establishing VEGF-C-driven meningeal lymphangiogenesis as neuroprotective.\",\n      \"evidence\": \"AAV-mVEGF-C intracerebrospinal delivery, lymphatic cauterization, snRNA-seq, CSF drainage assays, stroke model with MRI and behavioral outcomes\",\n      \"pmids\": [\"38442272\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether endogenous meningeal VEGF-C plays a role in stroke outcome unknown\", \"Neuroprotective pathways downstream of enhanced drainage not mechanistically defined\", \"Translational relevance to human stroke not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include: the full ternary structure of VEGF-C/NRP2/VEGFR-3, how tissue-specific protease availability quantitatively tunes the VEGF-C activity gradient in vivo, the complete enhancer/promoter logic integrating the many identified transcription factors, and whether the immunomodulatory and hematopoietic functions of VEGF-C are clinically targetable independently of its lymphangiogenic role.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No ternary receptor complex structure available\", \"Quantitative in vivo protease contribution mapping lacking\", \"Integration of multiple transcriptional inputs at the VEGF-C locus not modeled\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 5, 6, 7, 8, 21, 22, 26]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 9, 17]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 3, 5, 6, 10, 21, 22, 24, 26]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [26, 27]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 9]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FLT4\",\n      \"KDR\",\n      \"NRP2\",\n      \"ITGA9\",\n      \"FURIN\",\n      \"ZFP36\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}